This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by King, S. B. Search for Related Content PubMed PubMed Citation Articles by King, S. B., III Related Collections Other Treatment

(Circulation. 2007;115:1064-1066.)
© 2007 American Heart Association, Inc.

Editorial

Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS-II)

Prologue to COURAGE

Spencer B. King, III, MD

From the Fuqua Heart Center, Atlanta, Ga.

Correspondence to Spencer B. King III, MD, Fuqua Heart Center, 1938 Peachtree Rd NW, Suite 705, Atlanta, GA 30309. E-mail spencer.king@piedmont.org

Key Words: Editorials • coronary artery bypass grafting • therapy • coronary disease

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Clinical trials are organized for many different reasons. Most drug and device trials are designed to demonstrate the safety and efficacy of a drug or device, not to prove that they are the optimal treatments for patients. On the other hand, treatment strategy trials are designed to study the value of one therapeutic regimen compared with another when equipoise or confusion exists regarding which course to pursue. Assumptions are based on prior knowledge and opinion; in the case of coronary artery disease, most trials have been divided into those studying patients who "need" revascularization (ie, EAST [Emory Angioplasty versus Surgery Trial], BARI [Bypass Angioplasty Revascularization Investigation], CABRI [Coronary Artery Bypass Revascularization Investigation], RITA [Second Randomized Intervention Treatment of Angina], GABI [German Angioplasty Bypass Intervention], ARTS [Arterial Revascularization Therapies Study], SOS [Stent or Surgery], ERACI II [Estudio Randomizado Argentino de Angioplastia vs Cirugia II], and meta-analyses of these trails^1,2) and those in whom medical therapy is judged to be a reasonable choice. The latter list is short—RITA-2 [Second Randomized Intervention Treatment of Angina]³ and the awaited COURAGE [Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation]⁴ and BARI 2D [Bypass Angioplasty Revascularization Investigation 2 Diabetes]⁵ trials.

Article p 1082

An assumption is made that patient groups can be identified that will be suitable candidates either for equipoise between 2 revascularization choices or for medical therapy versus revascularization. The study by Hueb et al⁶ in this issue of Circulation enrolled patients, most of whom would have been eligible for percutaneous coronary intervention . . . [Full Text of this Article]

This article has been cited by other articles:

				Treatment Strategies for Multivessel CAD, Compared Journal Watch Cardiology, May 9, 2007; 2007(509): 5 - 5. [Full Text]